NEW YORK (GenomeWeb) – Singulex plans to list its single-molecule counting Sgx Clarity instrument as a CE-marked in vitro diagnostic in Europe at the end of March and plans to submit it for US Food and Drug Administration clearance in the second half of the year, according to Singulex CEO Guido Baechler.

In an interview at the recent JP Morgan Healthcare conference in San Francisco, Baechler provided an update on the firm's activities in the immunodiagnostics space and in developing its single-molecule counting (SMC) technology for various applications.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.